摘要
目的探讨参芪扶正注射液对晚期非小细胞肺癌(NSCLC)化疗患者造血和免疫功能的影响。方法 137例确诊的晚期非小细胞肺癌患者随机分为试验组(65例)和对照组(72例)。试验组采用参芪扶正注射液联合化疗,对照组采用单纯化疗,连续治疗2个周期后评估患者的疗效。结果试验组患者的白细胞减少及消化道反应显著低于对照组(P<0.05);试验组患者的白细胞介素2(IL-2)、淋巴细胞转化率、总T淋巴细胞(CD+3)、辅助T淋巴细胞(CD+4)和自然杀伤细胞(NK)升高程度显著高于对照组(P<0.05),而细胞毒T淋巴细胞(CD+8)、肿瘤坏死因子α(TNF-α)降低程度显著低于对照组(P<0.05)。结论参芪扶正注射液能保护骨髓,促进造血,具有抗肿瘤作用。参芪扶正注射液能提高患者的免疫力,减轻化疗药物的不良反应。
Objective To investigate the clinical efficacy of Shenqi Fuzheng Injection combined with chemotherapy on patients with advanced non-small cell lung cancer(NSCLC). Methods 137 cases with NSCLC were divided into observation group and control group. The observation group was treated by Shenqi Fuzheng Injection combined with chemotherapy, and the control group was treated by simple chemo- therapy. After 2 cycles of treatment, the efficacies of the two groups were assessed. Results The gastroin- testinal reaction and leukopenia of the observation group were significantly less than those of the control group(P 〈0. 05), and the increased degrees of the IL-2 ,the lymphocyte conversion rate, CD3 + , CIM + and NK in the observation group were significantly higher than those of the control group(P 〈 0. 05 ). However, the reduced degrees of the CD8 + TNF-α were significantly lower than those of the control group( P 〈 0. 05 ). Conclusion Shenqi Fuzheng Injection could protect the marrow, promote hematopoietic, be of anti-tumor effect, improve the patient's immunity, and reduced toxicity of chemotherapy.
出处
《中国肿瘤临床与康复》
2014年第4期463-465,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
癌
非小细胞肺
参芪扶正注射液
药物疗法
Carcinoma, non-small cell lung
Shenqi fuztleng injection
Drug therapy